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Although the discovery and characterization of multiple tumor antigens have sparked the
development of many antigen/derived cancer vaccines, many are poorly immunogenic
and thus, lack clinical efficacy. Adjuvants are therefore incorporated into vaccine
formulations to trigger strong and long-lasting immune responses. Adjuvants have
generally been classified into two categories: those that ‘depot’ antigens (e.g. mineral
salts such as aluminum hydroxide, emulsions, liposomes) and those that act as
immunostimulants (Toll Like Receptor agonists, saponins, cytokines). In addition,
several novel technologies using vector-based delivery of antigens have been used.
Unfortunately, the immune system declines with age, a phenomenon known as
immunosenescence, and this is characterized by functional changes in both innate and
adaptive cellular immunity systems as well as in lymph node architecture. While many of
the immune functions decline over time, others paradoxically increase. Indeed, aging is
known to be associated with a low level of chronic inflammation—inflamm-aging. Given
that the median age of cancer diagnosis is 66 years and that immunotherapeutic
interventions such as cancer vaccines are currently given in combination with or after
other forms of treatments which themselves have immune-modulating potential such as
surgery, chemotherapy and radiotherapy, the choice of adjuvants requires careful
consideration in order to achieve the maximum immune response in a compromised
environment. In addition, more clinical trials need to be performed to carefully assess how
less conventional form of immune adjuvants, such as exercise, diet and psychological
care which have all be shown to influence immune responses can be incorporated to
improve the efficacy of cancer vaccines. In this review, adjuvants will be discussed with
respect to the above-mentioned important elements.
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Cuzzubbo et al. Cancer Vaccines: Adjuvant PotencyINTRODUCTION
Therapeutic cancer vaccines represent an attractive strategy to
stimulate protective anti-tumor immunity in combination with
standard therapies. Cumulative data have confirmed the efficacy
of cancer vaccines in many murine tumor models, as well as inFrontiers in Immunology | www.frontiersin.org 2phase I and II clinical trials. In view of these promising results,
numerous clinical trials are ongoing. Figures 1 and 2 summarize
open cancer vaccine trials, distinguished by trial phase, cancer
type and vaccine type (Figure 1) and by adjuvant and
combinatorial treatments used (Figure 2). However, cancer
vaccines have not yet achieved significant clinical efficacy inA
B
FIGURE 1 | Open cancer vaccine trials. Cancer vaccine trials listed as open at ClinicalTrials.gov on August 2020. The number of trials for each cancer type (A) and
for each vaccine type (B) are shown in the bar graph subdivided into phase I, II, and III/IV. Viral vector vaccines include adenovirus and poxvirus, but also trials using
yeast-loaded antigens and one using Salmonella-loaded antigens. Cancers with less than 5 open clinical trials are not shown. “In situ vaccinations” (intralesional
injection of immune- modulatory molecules) are not included in these graphs. HPV, Human Papilloma Virus; CRC, colorectal cancer; VLP, virus like particle.February 2021 | Volume 11 | Article 615240
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rather anecdotal (48, 49). The reasons for those failed trials are
not fully understood but are most likely related to the stage of the
disease treated, an inherent difficulty to mount a strong cellular
immune response to non-live vaccine entities when older and the
choice of antigens, adjuvant and the suppressive nature of the
tumor microenvironment. Among these reasons, the difficulty of
achieving strong cellular immune responses is likely a major
factor to consider. In contrast to prophylactic vaccines against
infectious agents that usually trigger humoral responses,
therapeutic cancer vaccines aim to promote T cell immune
responses for effectiveness. Moreover, very limited
considerations have been given to the pharmacokinetic profile
of the antigen/adjuvant administration strategy and,
consequently, the required durable and effective long-term
CD4+ and CD8+ T cell responses are not achieved. AsFrontiers in Immunology | www.frontiersin.org 3mentioned, the developed tumor microenvironment is typically
immunosuppressive and is characterized by the presence of
exhausted T and NK cells and the accumulation of several
suppressive immune cells, such as T regulatory cells, T helper
type-2 (Th2) CD4+ T cells, tumor-associated macrophages
(TAMs), and myeloid-derived suppressor cells (MDSCs) (50–
53), in addition to which the activation state of T cells will be
regulated by co-inhibitory pathways. However, the approval of
the first cancer vaccine (Provenge®) in 2010 spurred hope (54),
as did the reported clinical effects and efficacy of checkpoint
inhibitors in some advanced cancer patients. However, global
availability of the former is limited as the EMA approval was
withdrawn in 2015 (55) and the clinical efficacy of the latter is
restricted to a few cancers. Nonetheless, many combination
strategies involving immune-based therapies and checkpoint
inhibition approaches are currently being tested in phase IIIA
B
FIGURE 2 | Adjuvants and combinatorial immunomodulatory therapies being used in cancer vaccine trials. Cancer vaccine trials listed as open at ClinicalTrials.gov
on August 2020. The number of trials using each adjuvant (A) and associating each immunomodulatory therapy with the cancer vaccine (B) are shown in the bar
graph. Adjuvants and combinatorial therapies used in less than 2 clinical trials are not shown. GM-CSF, Granulocyte-macrophage colony-stimulating factor; IL-2,
interleukin-2; Td, Tetanus/diphtheria toxoid; HSP, heat shock protein; CAF09b, cationic liposomes (DDA-MMG1) with complex bound synthetic double-stranded
RNA (Poly(I:C)2); IL-12, Interleukin- 12; P64k, Neisseria meningitides protein; PD-1, Programmed cell death 1; PD-L1, Programmed cell death ligand 1; CTLA-4,
cytotoxic T-lymphocyte-associated protein 4; RT, radiotherapy; M7824, fusion protein composed of a human IgG1 monoclonal antibody against PD-L1 fused with 2
extracellular domains of TGF-bRII; IFNalfa, Interferon alfa; IDO1, indoleamine 2,3-dioxygenase 1; ALT-803, IL-15 superagonist; Other vaccines, Salmonella,
pneumococcal vaccines; HSC, hematopoietic stem cells.February 2021 | Volume 11 | Article 615240
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environment, a key factor is to initiate vaccination in tumor
indications early on in the disease, non-metastatic, as the lesion
size may impact the effectiveness of the treatment (56). This
strategy is however hampered by lack of end-points that
facilitates studies that fall within a time-frame that can be
viable for the industry sponsored clinical trials.
Another potentially confounding issue with regards to the
efficacy of cancer vaccines is age, given that the median age of
cancer diagnosis is 66 years, and the immune system is known to
de c l i n e w i t h ag e . Th i s phenomenon , known a s
immunosenescence, is characterized by functional changes in
both innate and adaptive cellular immunity as well as in lymph
node architecture. While many of the immune functions decline
over time, others paradoxically increase. Indeed, aging is known
to be associated with a low, but persistent level inflammation.
“Inflamm-aging” also leads to dysregulation of innate and
adaptive immune cells (57–59).
It is therefore essential that the choice of adjuvants is carefully
optimized for each vaccine formulation, as well as for each
patient, in order to break immune tolerance and achieve
maximum immune responses and clinical efficacy, even in
such a compromised environment. Most cancer antigens are
poorly immunogenic and adjuvants are required to (i) prolong
the antigen availability at the injection site (“depot” effect); (ii)
activate the innate immunity; (iii) direct the immune response
toward T helper type-1 (Th1) responses; and (iv) to mitigate the
tumor/associated immune suppression (60, 61). Based on
function, classical adjuvants have generally been divided into
two categories: the immunostimulatory adjuvants (cytokines,
Toll-Like receptor agonists, saponins …) and “depot”
adjuvants (e.g. mineral salts such as aluminum hydroxide,
emulsions, liposomes). Although practical, this classification is
today rather simplistic since some delivery systems can also
activate innate immunity by creating local proinflammatory
reactions (62). Novel RNA-based vaccines have an inherited
adjuvant capacity that has also been associated with problematic
toxicity, handled by elegant design and formulation (63). As such
RNA-based vectors, which have had so far been developed for
cancer treatment, are now in a record development program
reaching the society in response to the COVID-19 pandemic.
This also sets the scene for many novel indications ahead
(64, 65).
In this review, adjuvants approved for human use will be
discussed with respect to the above-mentioned elements.
Importantly, new forms of adjuvants including exercise,
microbiota and the psychological status of the patient prior to
immunization will also be discussed.IMMUNOSTIMULATORY ADJUVANTS
Immunostimulant adjuvants likely constitute the most
promising strategy to potentiate immune responsiveness in
elderly cancer patients. Numerous defects in the innate and
adaptive immune system have been indeed described in elderly
individuals. Age-related reductions in levels of majorFrontiers in Immunology | www.frontiersin.org 7histocompatibility (MHC) class II expression as well as
dysregulation of cellular signaling in human and murine
monocytes compromise the efficiency of antigen presentation
to T cells (66–68). Studies on peripheral blood mononuclear cells
(PBMCs) from elderly donors have also revealed that aged
dendritic cells (DCs) have a reduced capacity for producing
inflammatory cytokines in response to inflammatory stimuli, and
particularly to several Toll-like receptor (TLR) ligands, as well as
an impaired ability to present antigens to T cells (59, 69–71).
Alongside defects in innate immune potential, numerous reports
have described the phenomenon of T cell immunosenescence, an
event which primarily results from thymic involution which
leads to a contraction of the naïve T cell compartment and a
predominance of terminally differentiated memory T cells in the
periphery (72, 73). Other studies suggest that chronic latent
infections, such as cytomegalovirus (CMV), could also play a
crucial role in T cell immunosenescence in the CD4+ T cell
compartment, as well as in the naïve and memory CD8+ T cell
compartments (74, 75). Permanent CMV infection stimulates
the expansion of CMV-specific memory CD8+ T cells and could
thus impact on the ability of an individual’s T cells to elicit a
response against new antigens (76). Additionally, the chronic
inflamm-aging status observed with age has been associated with
diminished expression of the costimulatory receptor CD28 on T
cells because of persistently increased levels of TNF-a (77–79).
CD28 is vital for efficient T cell activation, reduced levels of
which have been correlated with poor immune responses after
vaccination among older people (80, 81).
Cytokines
The use of cytokines in cancer immunotherapy and specifically
in cancer vaccine formulations is becoming more prevalent as
they can elicit both cellular and humoral immune responses.
IFN-a, IFN-g, IL-2, IL-12, IL-15, IL-18, IL-21 have especially
demonstrated immunological efficacy when used as part of a
vaccine adjuvant strategy (50). However, to date, GM-CSF
(granulocyte macrophage colony-stimulating factor) is the
immunostimulatory cytokine which has been most widely used
in clinical vaccine trials (Figure 2A). GM-CSF has been reported
to induce strong T cell responses as well as to inhibit tumor
growth in both whole tumor cell and peptide vaccines in
preclinical studies (82) by recruiting and activating antigen-
presenting cells (APCs) at the injection site. However, GM-
CSF as vaccine adjuvant has delivered conflicting results in
clinical trials. In some trials, GM-CSF has shown only weak
effects in potentiating immune response of cancer vaccine (83,
84) and in others no additional positive effect was reported when
associated with Montanide (85, 86). However, the only FDA
approved cancer vaccine, Provenge®, bases the adjuvant effect on
a fusion protein that contains GM-CSF and reported an OS
benefit in patients with metastatic castrate-resistant prostate
cancer. However, in phase II and III trials testing Provenge®,
the exact role/influence of GM-CSF over clinical efficacy was not
thoroughly investigated. In addition, two trials containing GM-
CSF in the vaccine formulation resulted in decreased cell-
mediated immune responses and shorter survival of patients
with melanoma (87, 88), however it is also possible that in thisFebruary 2021 | Volume 11 | Article 615240
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impact on the results. Indeed, lower doses of GM-CSF in water
formulations could shape the lymph node differently compared
to a montanide based formulation. Interestingly, daily doses of
GM-CSF over 100 µg/day given repeatedly have been reported to
promote the expansion of myeloid-derived suppressor cells
(MDSCs) and inhibit T-cell function (89). While GM-CSF as
an adjuvant in prime/boost administration given at lower doses
has shown good adjuvant capabilities and is an adjuvant
commonly used in many vaccine formulations due to the
expanded knowledge of the adjuvant (Table 1, Figure 2A).
Systemic use of cytokines such as IL-2 or GM-CSF in
combination with other immunotherapies have also shown
clinical efficacy (3, 90). It is therefore extremely important to
optimize the schedule, formulation and the dose of cytokine in
order to avoid/limit systemic side-effects.
Toll-Like Receptor Ligands
The stimulation of professional APCs such as neutrophils, B
cells, macrophages and DCs is an efficient approach to boost the
efficacy of cancer vaccines, especially in immunocompromised
individuals, such as cancer patients and more generally the
elderly. However, as indicated above, age-related deficiencies in
monocyte and macrophage function mediated by functional
dysregulation of cellular signaling, and specifically of Toll-like
receptor (TLR) pathway have been described. Activation of
APCs relies upon stimulation of pathogen recognition
receptors (PRRs) by conserved pathogen-associated molecular
patterns (PAMPs) expressed on microbes, or endogenous
danger-associated molecular patterns (DAMPs) released by
injured cells. TLRs recognizing PAMPs and DAMPs under
physiological conditions are expressed either on the cell
membrane (TLR1, -2, -4, -5, -6, and -10) or on endosomal
membranes within the cell (TLR3, -7, -8, and -9) according to the
ligand - membrane TLRs bind lipids and proteins whereas
intracellular TLRs bind nucleic acids (91, 92). PRR activation
induces the release of chemokines and inflammatory cytokines,
the recruitment of innate and adaptive immune cells, and
stimulation of the APCs themselves via the induction of
costimulatory molecule expression, including B7.1 (CD80),
B7.2 (CD86) and CD40.
Studies on peripheral blood mononuclear cells (PBMCs) from
elderly donors have shown that that aged DCs have a diminished
ability in producing cytokines in response to inflammatory
stimuli, and particularly to TLR1/2 and TLR7/TLR9 ligands, as
well as an impaired capacity for presenting antigens to T cells
(69–71). Such deficiencies have been associated with a decreased
activity of PI3K that results in aberrant activation of NF-kB and
therefore a weak, but chronic inflammatory state characterized
by continuous release of IL-6 and TNF-a cytokines (93), the so-
called phenomenon of inflamm-aging. The overall result is a
compromised ability of DCs to orchestrate an efficient adaptive
immune response in elderly individuals (59).
In view of these defects on DCs, TLR ligands which mimic
PAMPs represent promising adjuvant candidates for cancer
vaccines in elderly individuals. Synthetic TLR3, TLR7 andFrontiers in Immunology | www.frontiersin.org 8TLR9 agonists are likely the best candidates, as they mimic
viral RNA and DNA PAMPs (94) which generally generate
robust cytolytic CD8+ T-cell responses (95, 96). Specifically,
TLR3 recognizes viral dsRNA and their synthetic analog Poly
I:C (97, 98); TLR7 binds viral ssRNA, whereas TLR9 interacts
with unmethylated CpG DNA from bacteria and viruses (91, 92).
Three TLR ligands are FDA-approved for cancer therapy:
Bacillus Calmette-Guérin (BCG), a TLR2/4 ligand, the TLR4
ligand monophosphoryl lipid A (MPLA) and the TLR7 agonist
imiquimod. However, many other TLR agonists have proven
their efficacy in pre-clinical and clinical studies.
The use of TLR agonists constitutes an efficient way to boost
the efficacy and potency of cancer vaccines thanks also to their
interaction with other immune and non-immune cells which can
express TLRs, including T-cells and cancer cells. Indeed, poly I:C
(TLR3 agonist) has been reported to stimulate the proliferation
and survival of both CD4 and CD8 T cells in a CF-kB-dependent
manner (99, 100). Additionally, in human CD4+ Th cells, the
stimulation of TLR7/8 and TLR5 by resiquimod and flagellin
increases IFN-g, IL-2, and IL-10 release and enhances
proliferation in an APC-independent manner (101). Other
studies have shown similar effects of TLR9 stimulation on the
survival and proliferation of CD4+ and CD8+ T-cells. This effect
was mediated by NF-kB signaling and was associated with
increased expression of the anti-apoptotic protein Bcl-xL (99).
Furthermore, TLR9 stimulation of CD4+ T-cells can render them
resistant to the immunosuppressive effects of regulatory T cells
(Tregs) (102, 103).
Beside APCs and T cells, TLRs are also expressed by amultitude
of cancer cells. Their direct effect on cancer cells is not completely
defined, and probably much less important than their immune
effects. The activation of TLR2 and TLR4 in cancer cells has been
linked to tumor-promoting effects by promoting vascularization
and cell invasion via the induction of COX-2, PGE2 and IL-8 (104,
105). Similar to TLR2 and TLR4, TLR7/TLR8 overexpression in
lungcancer cells has beenassociatedwithpro-tumoreffects through
the activation of NF-kB and resulting in upregulation of
inflammatory cytokines, the anti-apoptotic Bcl-2, the angiogenic
VEGFR2 and several chemokine receptors associated with cell
migration (106). TLR3 stimulation by Poly I:C or BCG has been
implicated in promoting tumor cell death in amultitude of cancers,
including breast cancer, colon cancer, bladder cancer, head and
neck carcinoma, pharynx carcinoma, hepatocellular carcinoma,
lung cancer and melanoma. TLR3 polymorphisms have also been
linked toan increased riskof several cancers suchasnasopharyngeal
carcinoma, breast cancer, cervical cancer, and Hodgkin’s disease
(107). However, TLR3 activation has been reported to induce
cancer progression as well by the induction of VEGF, MMP9 and
uPAR via Myc- and MAPK signaling (108). TLR5 signaling on
cancer cells has been reported to inhibit tumor growth in various
cancers, including breast cancer (109), head and neck cancer (110)
and colon cancer (111). On the contrary, TLR5 stimulation in
gastric cancer cells, notably by H. pylori, has been reported to
increase IL-8 production, tumor cell proliferation as well as TNF-a
expression levels that can support the suppressive effects of Treg
cells (112, 113). Depending upon tumor cell types, TLR9 activationFebruary 2021 | Volume 11 | Article 615240
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induce caspase-dependent apoptosis (119, 120). The TLR9
agonist CpG-ODN has proved to be moderately effective in
glioblastoma patients when injected intratumorally (121, 122).
In summary, various TLRs can be expressed on numerous
cancer cell types and TLR3 and TLR5 appear to be the most
promising adjuvants for combining direct anti-tumor properties
with immunostimulant effects on APCs and T cells. However, the
final effect of each TLR agonist relies on its immunostimulant
properties. Therefore, the choice of the TLR agonist should be
primarily driven by its ability to trigger T cell response in humans,
which should be defined on a case-by-case basis for a given antigen.
Saponins
Saponin adjuvants are extracts from the plant Quillaja saponaria
and possess potent inflammatory properties. QS-21 is the most
commonly used adjuvant in vaccine formulations (123) and its
immunogenicity has been attributed to the triterpene aldehyde
group, which is capable of triggering the ASC/NALP3
inflammasome signaling and thus stimulating the conversion
from precursor to activated forms of IL-1 b and IL-18 (124). The
adjuvant QS-21 has been reported to elicit robust T-helper 1,
CD8+ T cell and humoral responses in preclinical studies. Besides
such immunogenic properties, QS-21 strongly activates the
inflammasome thus causing cell membrane lysis and apoptosis
of APCs (124). QS21 has also been tested in clinical trials, mostly
as adjuvant of cancer vaccines targeting ganglioside antigens and,
despite strong humoral responses, no significant cellular immune
responses were observed. Its efficacy in cancer vaccine appears
thus limited.
QS-21 has also been used as part of more complex vaccine
formulations combining multiple adjuvants, for instance
ISCOMATRIX incorporating the saponin adjuvant with
antigens in a micellar structure (125), and AS01 and AS15
combining QS-21 with MPL (126).
Stimulator of Interferon Genes Agonists
Stimulator of Interferon Genes (STINGs) are transmembrane
proteins that induce a robust Type I IFNg response upon
activation and are expressed at the highest levels by T cells.
STING activation can lead specifically to T cell apoptosis since
DCs or macrophages do not exhibit such sensitivity (127).
STING agonists are combined with adjuvant systems that
specifically target myeloid cells (128) and are capable of
reprogramming MDSCs towards a DC-like phenotype
expressing IL-2 and co-stimulatory molecules (129). However,
differential binding properties of these agonists to human and
murine cells poses a challenge for the development of
clinical strategies.
Ideally, implementation of STING agonists in cancer vaccines
should be combined with potent adjuvant/delivery systems such
as liposomes or polymeric nanoparticles or inorganic materials
to minimize systemic dissemination that can cause toxic cytokine
storm and limited bioavailability.
Currently, ADU-S100 and MK-1454 are being tested along
with immune checkpoint inhibitors (ICIs) in early phase clinical
trials in patients with advanced/metastatic solid tumors orFrontiers in Immunology | www.frontiersin.org 9lymphomas (NCT03172936, NCT03010176). Both require
accessible lesions for intratumor injections to avoid
systemic toxicity.DELIVERY SYSTEM AS ADJUVANTS
The classical classification of delivery systems and
immunostimulant adjuvants is practical, but not dichotomic
since several adjuvants can act as a delivery platform for
antigens, while also having some immunomodulating
properties. Adjuvants traditionally classified in this category
mainly act by improving antigen stability, preventing antigen
degradation and finally optimizing its processing and
presentation to T cells. The most important delivery system
adjuvants and their mechanisms are described below.
Mineral Salts
Alum is by far the most used adjuvant in approved human
vaccines against various infectious organisms (130). Aluminum-
based adjuvants are traditionally classified as a delivery system
type because their depot effect at the injection site leads to a slow
release of the antigens. However, recent reports showed that
alum is also capable of stimulating the innate immune response
by activating the NLRP3/NALP3 inflammasome complex and
triggering the release of uric acid (131, 132).
The adjuvant effect of alum in vaccines against infectious
agents essentially results from an induction of a sustained Th2
response, as characterized by antibody production, but generally
fails to mount a strong cellular (Th1)-based immune responses
that are necessary for robust protective anti-tumor immunity.
Hence, the use of aluminum-based adjuvants in cancer vaccines
is of limited use (130). However, studies have been able to show
that alum can also induce a cytotoxic immune response (133), as
well as a clinical efficacy in cancer patients in terms of survival
(racotumomab-alum vaccine directed against NeuGcGM3
tumor-associated ganglioside) (19). In addition, recent studies
have shown that alum can elicit robust immune responses and
have anti-tumor efficacy (in terms of inhibited tumor growth and
prolonged survival) when used in nanoscale (134). Nano-
aluminum adjuvants can indeed carry more antigens and more
efficiently present them to antigen-presenting cells (APCs) in
lymph nodes compared to traditional aluminum salt adjuvants
which tend, instead, to remain at the injection site because of
their positive charge and large particle size (135, 136).
Emulsions
Emulsions are typically classified as water-in-oil (W/O) or
oil-in-water (O/W) formulations and mainly act as delivery
system of antigens in the injection site, thereby allowing a slow
and prolonged release of the latter. Nevertheless, they also have
some immune adjuvant properties by inducing local inflammation
and promoting the recruitment of APCs as well as their phagocytic
uptake of antigen (137–139).
Complete Freund’s adjuvant (CFA) was the first water-in-oil
emulsion to be developed (1930). CFA is a highly potent
adjuvant which contains heat-killed mycobacteria but inducesFebruary 2021 | Volume 11 | Article 615240
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site of injection. Given its adverse effects, CFA is not permitted
for use in humans.
Incomplete Freund’s adjuvant (IFA) is also aW/Oemulsion, but
without mycobacteria. IFA induces more manageable adverse
events than CFA and is the “golden standard” of this group of
adjuvants for assessing the immunogenicityof antigens inmice. IFA
has proven to induce both cellular and humoral immune responses
(140–143) and its human equivalent, Montanide ISA-51, has been
and continues to be widely used in peptide cancer vaccine
formulations in many trials (melanoma, renal carcinoma) (144,
145) (Figure 2A). Other studies, however, have shown negative
effects of IFA and, more generally, of all W/O emulsions. The slow
persistent releaseof the antigen coupledwith the local inflammation
induced by the emulsion itself can actually result in the
sequestration of primed CD8+ T cells at the injection site, when
using short peptides, leading to limited T cell homing to the tumor
and T cell tolerance (146–149). In addition, W/O emulsions are
usually associated with Toll-Like receptor (TLR) agonists and
numerous studies have reported a detrimental effect of W/O
emulsion on T cell responses triggered by TLR agonists (150).
MF59 is an O/W squalene-based emulsion that is currently
licensed for human influenza vaccines (151, 152). As for other
adjuvants historically included in this group, MF59 also appears
capable of triggering cellular and humoral responses. Indeed, MF59
can promote leukocyte recruitment by inducing macrophages and
dendritic cells to secrete several chemokines. MF59 has proven to
be effective in elderly subjects in human trials and is currently used
in a flu vaccine for individuals > 65 years. The use of MF59 is
limited in cancer vaccine strategies because of the primal Th2
response. However, in combination with CpG ODN (cytosine
guanine dinucleotide oligodeoxynucleotides, TLR9 agonist),
MF59 has proven to induce effective anti-tumor responses in
several murine cancer models (94, 153).
Liposomes
Liposomes are phospholipid vesicles which are used as delivery
carriers for antigen or also immunostimulatory adjuvants (154,
155). Allison and Gregoriadis, in 1974–1976 innovated the
liposomes and since then all their derivative nanovesicles have
become important delivery systems for vaccines. Positively
charged liposomes have been reported to trigger more potent
immune responses compared to negatively charged liposomes.
This efficacy is attributed to both more efficient phagocytosis of
positively charged liposomes by APCs (156) and reduced
lysosomal degradation of antigens because of a higher pH
(157). The key advantages of liposomes are their versatility,
plasticity, biocompatibility, and biodegradability. Various
choices for the composition and preparation can be achieved
from a selection of lipids to target the desired charge, size,
distribution, traveling and location of antigens or adjuvants for
cancer vaccines (155). However, using liposomes for human
applications is restricted due to the lack of stable manufacturing
of vaccine-grade liposomes and their high cost (155, 158). To
resolve these obstacles in co-formulation, a manufacturable,
synergistic anionic liposome platform with TLR4/TLR7
agonists ready for use in clinical trials has been developed (159).Frontiers in Immunology | www.frontiersin.org 10Many animal models using liposomes as delivery agents have
shown that liposomal cancer vaccines have superior efficacy over
the non-liposomal vaccines (158, 160, 161). In mice challenged
with Lewis lung carcinoma cells, liposomal vaccines combining
basic fibroblast growth factor and the adjuvant monophosphoryl
lipid A (MPLA) induced tumor-specific antibodies and Th1-type
immune responses (160). Liposomal delivery of the lipid antigen
a-galactosylceramide induced anti-tumor immunity that was
protective against lung metastases in 65% of B16 F10-tumor-
bearing mice, by activating the NKT cells in the spleen (161).
Park et al., developed a peptide-CpG-liposome complex vaccine
which was proven to efficiently elicit humoral responses (anti-
hTM4SF5 antibodies) and inhibit cancer growth in various
murine tumor models (pancreatic cancer, metastatic
hepatocellular cancer, colon cancer, lung metastasis model)
(162). Liposomal vaccines have also been reported to elicit
strong cytotoxic T lymphocyte (CTL) responses against tumor-
associated peptides, as in the case of Lip-DOPE-P5-MPL, where
the P5 peptide was encapsulated in a complex of 5 lipids (DMPC,
DMPG, cholesterol, DOPE and MPLA) conjugated with
maleimide-PEG2000-DSPE (163). In a mouse model of
neuroblastoma, liposomal delivery of CpG ODNs has been
shown to elicit potent anti-tumor effects, whereas the CpG-
alone group failed (119). Liposomes were also proven to
increase the uptake and stimulation of APCs leading to anti-
tumor efficacy when used as delivery system of DNA or RNA
complexes in mice (164). Recently, a novel lipopolyplex vector
(multi-LP) was proposed for the in vivo delivery of mRNA by
incorporating the immune adjuvant a-galactosylceramide (a-
GalCer) and a multivalent cationic lipid to target the dendritic
cells (DCs) without cell-specific functionalization or
ligands (165).
In addition to the above, several clinical trials using liposomes as
carrier system for vaccine have reported safety, capability of inducing
prolonged antigen-specific CD4+ and CD8+ T cell responses, as well
as prolonged survival in various cancers, including non-small-cell
lung carcinoma (NSCLC) (166), melanoma (167, 168), follicular
lymphoma (169) ovarian (170), breast and prostate cancers (171).
In conclusion, liposomes are versatile delivery systems which
can load antigens, proteins, peptides, nucleic acids, and
carbohydrates, as well as for the formulation of new types of
vaccines targeting the lymphatic system or specific APCs such as
macrophages or DCs.
Virosomes
Virosomes are spheres of natural or synthetic phospholipids
(liposomes) incorporated into which are virus envelope
phospholipids and viral spike proteins. They were identified in
1975, but the first virosome-based vaccine in humans was
Inflexal V for influenza in 2009 (158). Virosome-based
vaccines are currently commercialized as preventive vaccines
for HPV16 and 18-related cancers (Cervarix™ and Gardasil®)
(172, 173). Virosomes were widely utilized in cancer vaccines
because they are incapable of replicating and therefore are not
infectious but retain the ability of the parenting virus while
carrying tumor-specific antigens to the APCs to induce
immunity (174). Thus, virosomes increase the tumor-specificFebruary 2021 | Volume 11 | Article 615240
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phase I clinical trial on metastatic breast cancer patients (177,
178). The main advantages of virosomes as efficient prophylactic
and therapeutic agents are tissue targeting, immune activation
and potentiation. Application of virosomes in cancer vaccine will
open a new prospective with multiple safe advantages as a unique
delivery system (179–181). Recently, adding magnetic agents to
HA-virosomes has been proposed as a ground-breaking
innovative platform for treating cerebral tumors by enabling
targeting using an external magnetic field from a magnetic
helmet (182).
Nanoparticles
Nanoparticle carriers have the advantage to specifically target the
APCs by various formations and strategies. The main types of
nanoparticle adjuvants under development include metals,
carbon nanotubes and polymers.
Metallic nanoparticles have various advantages over polymers
and liposomes thanks to their multifunctional properties such as
their small particle size, superparamagnetic properties and
biocompatibility. Metallic nanoparticles such as gFe2O3,
Al2O3, TiO2, ZnO, and SiO2 enhance immune responses
mainly by acting as antigen carriers that deliver directly to
APCs. Specifically, gFe2O3 with a positive surface charge can
be absorbed by proteins with negative charge, promote the
immune response and enable labeling and tracking cells at the
same time. Enhancing the cross-presentation ability of DCs and
T cell activation confers great potential on superparamagnetic
iron oxide nanoparticles as adjuvants. However, the mechanisms
are still not well defined (183). Gold nanoparticle platforms have
been more widely applied in tumor models, challenges with
regards to approval from the Food and Drug Administration
(FDA) remain a challenge for translating these into the clinical
setting (184). Recently, gold nanoparticle surfaces were coated
with high cargo density of polyelectrolyte multilayers or peptides
to promote the antigen-specific T cell response (184, 185).
Carbon nanotubes are extensively used in cancer therapeutics
due to their large surface area and good conjugation and
encapsulation properties. In the field of cancer vaccines,
carbon nanotubes have been especially proven to enhance the
embryonic stem cell-based cancer vaccine response in murine
colon cancer model (MC38) (186). Despite the encouraging
results in pre-clinical studies, the use of carbon nanotubes in
humans has been hampered by their potential toxicity.
Conflicting data is indeed reported on carbon nanotubes
biocompatibility and biodegradability (187).
Although polymeric particles have been used in product
development for several decades, they have not until relatively
recently been considered for vaccine development. However,
PLGA (poly lactic-co-glycolic acid) nanoparticles have now
been approved for human use by the FDA and the European
Medicines Agency (EMA) after being considered as the most
nontoxic and slowly degraded vaccine delivery system (188) for
target-specific and controlled delivery of drugs, peptides, proteins,
antibodies and genes in cancer. Linear polyethyleneimine was
recently developed for chemical coupling of protein/peptideFrontiers in Immunology | www.frontiersin.org 11ligands to form nano-polyplexes with plasmid DNA or RNA
which deliver the nucleic acids into the targeted cells without
associated toxicity to healthy cells (189). The delivery of DNA and
mRNA using such an approach has a number of advantages,
including being safer alternatives to viral vectors, colloidal stability
(190, 191) can be exploited using injection-free gene delivery
systems (192–194), and the ability to modify with targeting
moieties like mannose (195).
In addition to the main nanoparticles above-mentioned, other
promising nanoparticles are under development as adjuvants in
cancer vaccines. For instance, to enhance the tumor penetration
capability, positively charged nanoparticles based on the most
abundant polysaccharide in nature (chitosan) have been
developed over two decades of research on very complex
optimized systems. Also, synthetic melanin nanoparticles have
been reported to be an innovative adjuvant for cancer vaccines,
in that they efficiently localize to draining lymphoid tissues and
exhibit strong immunostimulant properties when loaded with
both short and long peptides in mice (196). A melanin-based
vaccine in combination with a TLR9 has also proved to be a
strong anti-tumor efficacy in cancer murine models and
compares favorably with the classical formulation of IFA and
TLR9 agonist (197).
Current nanoparticle-based strategies in cancer vaccination
and immunotherapy vary. Therapeutic nanomaterials enhance
the efficacy of cancer vaccines by increasing the lymphatic
delivery of specific antigens or by combining targeting
approaches with stimulating materials to synergize and/or
modulate immune activation. Primarily, the nanocarriers load
the adjuvants by hydrophobic or electrostatic interactions which
elevate the immunogenicity of tumor antigens (198). The
potential co-delivery of antigens and adjuvants such as TLR
ligands to DCs can boost the induction of protective anti-tumor
immunity. Thus, the therapeutic cancer vaccine becomes
essentially a nano-package of antigen, adjuvant and nano-
carriers. For instance, the aliphatic polyesters PLGA and poly-
ϵ-caprolactone (PCL) have proven to be efficient vectors for
increasing their uptake by DCs due to their critical size, surface
charge, surface functionalization and route of administration
(199, 200). However, the efficacy of such an approach was proven
in minimal residual disease conditions instead of the typical
clinical condition of large bulky tumors. The co-delivery of
adjuvants with nano-based formulations enhances the cross-
presentation and/or skews the immune responses to the
desired CD4+ T helper phenotypes. Specifically, cancer nano-
vaccines co-deliver peptides and TLR9 agonists (201, 202), and
gold nanoparticles the anionic TLR3 agonist poly I:C co-
delivered with cationic antigen peptides (185). In addition,
nanoparticles can support a combinational use of adjuvants to
permit exploitation of synergy among certain TLR agonists (159,
203–205). A significant therapeutic example in a late-stage
murine melanoma model has been combining the peptide
epitope of tyrosine-related protein 2 (Trp2) and CpG-based
nano-vaccine with siRNA against TGF-b, which is one of the
major cytokines responsible for induction and maintenance of an
immunosuppressive tumor microenvironment (206). EffectiveFebruary 2021 | Volume 11 | Article 615240
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systems that retain their cargo under the physiological
condit ions and release ant igens in the endosomal
microenvironment (~pH 6) (207, 208). Alternatively, an
oxidation-sensitive polymersome can respond to the oxidative
environment of endosomes to trigger the delivery of antigens and
adjuvants in the cytosol (209). Furthermore, modification of
liposomes with a cell-penetrating peptide or gold nanoparticles
with tumor antigens has also been shown to promote cross-
presentation (210, 211).
Although several vaccination strategies have been tested in
vivo, therapeutic benefits remain mixed and a huge gap between
material research, preclinical experimentation and clinical reality
remains. Further research into the use of PLGA are warrantied to
bridge this gap (199). The delivery of whole-cell cancer vaccines
has been accomplished using a PLGA matrix containing tumor
lysate as the source of tumor antigens, granulocyte macrophage
colony-stimulating factor (GM-CSF) for recruitment of DCs in
situ, and CpG for DC activation. This PLGA matrix elicited
antigen-specific CD8+ T cells and increased both prophylactic
and therapeutic anti-tumor efficacy (212). Alternatively, plasma
membranes of tumor cells have been extracted and coated onto
polymeric nanoparticle cores along with the TLR4 agonist MPLA
as a tumor cell-mimicking cancer vaccine (198).
Although targeted delivery to DCs and the induction of CD8+
T cell responses can be achieved using nano-vaccines consisting
of CD40 Ab-modified nanoparticles (213), the efficiencies of DC-
targeting and induction of adaptive immune responses require
optimization as different DC subsets have characteristic sites of
tissue residence, receptor expression profiles and functions (214).
Moreover, targeting distinctive tissue sites such as murine
lymphoid tissue-resident CD8+ DCs and, for human,
CD141+BDCA-3+ DCs and Langerhans cells requires further
study for nano-vaccines (215, 216). The efficient draining of
nanoparticle carriers to lymphoid tissues has been qualitatively
and quantitatively demonstrated using fluorescent or contrast
agent-based imaging. For example, a polyester nanoparticle
system loaded with ovalbumin (OVA) has been labeled with a
near-infrared probe (216), and PLGA nanoparticles have been
designed to carry iron oxide particles conjugated with
fluorophore-labeled peptide antigen (217). Additionally,
synthetic melanin nanoparticles have efficiently localized to the
draining lymphoid tissues and have potent immunostimulant
properties when loaded with short or long peptides in murine
models (196, 197). Delivery systems having different particle
sizes composition, morphology, and surface chemistry of
particles are promising candidates to be translated into clinics
to confirm delivery to the draining lymphatics (218).
Novel Biomolecule-Based Targeting
Strategies
To induce tumor immunity, Fc gamma receptor (FcgR) targeting
strategies coupled with antigens have been explored for the
purpose of activating both CD8+ and CD4+ T cells. FcgR
cross-linking to improve T cell priming can be achieved via
the formation of immune complexes in vivo (219). For vaccineFrontiers in Immunology | www.frontiersin.org 12purposes, the conjugating of a universal tetanus-derived
synthetic peptide (minimal tetanus toxin epitope, MTTE) with
viral or tumor derived antigens - also in the form of synthetic
peptides - can facilitate immune complex formation and FcgR
cross-linking which results in DC and T cell activation (220,
221). Alternative strategies to target DCs include fusion strategies
based on IgG scaffolds that introduce antigen epitopes in the
CDR region and vaccine delivery using a DNA based vector
system with the aim to target the high affinity FcgRI (222, 223).
The goal and advantage of these technologies is to provide a
single drug entity which can harness both the adjuvant and
targeting of the antigen to APCs, as well as the potential antigen
half-life extension that the methodology provides. It also ensures
that HLA/peptide off-rate is not the determining factor for
antigen delivery to the lymph node. The challenges presented
by these approaches are the species differences in the receptor
and immunology biology as well as the costly production of, for
example, antibody-based therapies, if used as such.COMBINATORIAL STRATEGIES TO
IMPROVE CANCER VACCINE EFFICACY
IN THE IMMUNOSUPPRESSIVE CONTEXT
OF CANCER PATIENTS
Combining Different Adjuvants to Induce
More Extensive Immune Responses
The ideal adjuvant for a cancer vaccine formulation should (i)
protect antigens from degradation, (ii) stimulate efficient uptake
of the antigens by APCs, (iii) activate these APCs to efficiently
present the antigen to T cells in order to trigger a strong Th1/
CTL response and long-term memory T cells. One single
adjuvant may not provide all of these effects at the same time.
Thus, a combination of a delivery system adjuvant and an
immunostimulant adjuvant is commonly chosen for cancer
vaccine formulation (Figure 3). For instance, montanide (for
depot effect) and a TLR ligand (for APC stimulation) constitutes
a common combination of adjuvants for anti-cancer vaccine
(224). Based on preclinical studies, combining several TLR
agonists or anti-CD40 antibodies with a TLR ligand could
potentiate the adjuvant effect by activating different APCs
simultaneously and further inducing more extensive CD8+ T
cell responses (225–227). However, the realization that
formulations and the design of the antigen can negatively
influence the expansion of a systemic immune response is of
importance and should trigger in depth characterization of both
the design and physiochemical properties of vaccine
components , and the pharmacokinetic profi les and
administration dose and schedule, to achieve proper anti-
tumor responses.
Another strategy to enhance the efficacy of cancer vaccines
could be combining it with systemic immunostimulatory agents
such as cytokines, especially IL-2 or GM-CSF. Systemic IL-2 in
combination with gp100 peptide-vaccine in patients with
melanoma has delivered significant efficacy in terms ofFebruary 2021 | Volume 11 | Article 615240
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2 monotherapy. However, at such high doses, IL-2 caused
numerous toxicities if not formulated correctly (3).
Blocking VEGF to Restore Tumor Vessels
and Promote T Cell Homing to Tumors
Following the induction of peripheral immune response by
cancer vaccine, specific anti-cancer T cells need to penetrate
the tumor to attack cancer cells. Unfortunately, the tumor
vasculature is reported to express reduced levels of leukocyte
adhesion molecules, such as intercellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1),
and an aberrant overexpression of immune checkpoints
including PD-L1, the death receptors FasL and TRAIL, and
IDO, all of which impede the infiltration and function of
activated T cells into/in the tumor microenvironment (228).
Anti-angiogenic treatments such as bevacizumab (vascular
endothelial growth factor—VEGF—inhibitor) have been reported
to restore a normal vasculature within tumors and increase the
expression levels of ICAM-1 (229). Additionally, VEGF has also
been proven to inhibit T cell and DC activation (230, 231).
Therefore, combining an anti-angiogenic treatment such as
bevacizumab (VEGF inhibitor) with vaccine seems a valid
strategy to enhance the anti-cancer T cells (triggered by the
vaccine) homing to tumor. Other molecules such as all-trans
retinoic acids, anti-inflammatory triterpenoid, tyrosine kinase
inhibitors (sunitinib), IL-12 and anti-IL-6R antibodies, anti-CSF-
1R, anti-CCL2 have been reported to reduce tumor infiltration by
MDSCs and improve the efficacy of cancer vaccines (232–237).Frontiers in Immunology | www.frontiersin.org 13Finally, STING agonists possess the ability to convert MDSCs from
a suppressive into a type-1 immune profile (129).
Depletion of Immunosuppressive
Leucocyte Populations by Combining
Chemotherapy With Cancer Vaccines
Chemotherapy has long been considered to conflict with
immunotherapies due to its leucocyte depleting effect.
However, several peripheral and intratumoral leucocyte
populations have immunosuppressive properties, thus reducing
the efficacy of tumor-reactive cytotoxic T lymphocytes CTLs. A
therapeutic strategy could thus rely on combining therapeutic
cancer vaccine with leucocyte-depleting chemotherapeutics that
target such populations.
Regulatory T (T reg) cells are particularly known for
inhibiting CTL functions through the release of the anti-
inflammatory IL-10, FGF-B and adenosine as well as the
‘consumption’ of IL-2 in the microenvironment, thereby
reducing its availability for T cells. Combining cancer vaccines
with molecules that can reduce the number of Treg cells, such as
cyclophosphamide or low dose temozolomide (TMZ) thus
constitutes another valid approach to improve the efficacy of
anti-tumoral CTLs (126, 238, 239). Several studies indicate that
3–7 days after these chemotherapies may be the best timing to
administer the cancer vaccine (84, 240, 241).
MDSCs represent another immunosuppressive leukocyte
population frequently found in the tumor microenvironment
which can limit the efficacy of anti-tumoral CTLs. Several
myeloablative chemotherapeutics are known to decrease bothFIGURE 3 | Improving the efficacy of cancer vaccines: Combinational approaches.February 2021 | Volume 11 | Article 615240
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taxanes, gemcitabine, 5-Fluorouracil (242–244). The rationale
of combining chemotherapy with therapeutic cancer vaccines to
deplete MDSCs and boost vaccine-induced CTL responses has
been reported in several studies (84, 238, 245). Specifically, in
carboplatin-paclitaxel regimen the normalization of myeloid
cells begins 2 weeks after the second cycle of chemotherapy
and the administration of cancer vaccine at this point resulted in
stronger vaccine-induced responses in preclinical and clinical
studies (246–249).
Other studies reported improved anti-tumor responses also
when chemotherapeutic agents were given simultaneously with
the vaccination, as in the case of metronomic cyclophosphamide
(170) or association of cyclophosphamide, paclitaxel and
docetaxel (250). Given these results, the optimal schedule may
be starting with chemotherapy cycles and following with
concomitant chemotherapy and vaccination.
Enhancing Cytotoxic T Lymphocyte
Function by Combining Cancer Vaccines
With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs), including antibodies
against programmed cell death protein-1 (PD-1) or its ligand
(PDL-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have
proven to enhance anti-tumor immunity and efficacy in several
cancers. However, a large subset of patients does not benefit from
ICI therapy, with a reported objective response rate for anti-PD1
varying from almost absent (pancreatic cancer, glioma,
microsatellite-stable colon adenocarcinoma) to 15–30% for
most cancers, and 50–80% for few cancers including
melanoma, Hodgkin lymphoma, squamous cell carcinoma and
Merkel carcinoma (251). This low response rate observed in
most cancers is likely related to a limited specific T cell response
developed against cancer cells, especially for tumors with a low
mutational burden. Therefore, combining a cancer vaccine,
which can elicit specific T cell responses, and ICIs represents
an attractive therapeutic option. Based on positive results in pre-
clinical models (252–254), several clinical trials are now
evaluating novel personalized vaccines against neoepitopes
specific of each pat ient in combinat ion with ICIs
(NCT02950766, NCT02897765, NCT03289962) (Figures 2B
and 3). However, few studies address the point of the choice of
a specific molecule. One preclinical study reported that anti-4-
1BB antibody was superior to achieve anti-tumor efficacy in
combination with peptide cancer vaccine compared with other
immunomodulating antibodies (255). Also, the timing of
combination therapy is rarely discussed in clinical trials, but
some reports suggest that immune checkpoint inhibitors better
synergize with the vaccine when administered at the time of the
boost rather than at the prime (256).
Combining Cancer Vaccine With
Radiotherapy to Favor Antigen-
Presentation by Cancer Cells
Numerous studies have shown the immunogenic properties of
radiotherapy. Tumor irradiation can indeed induceFrontiers in Immunology | www.frontiersin.org 14immunogenic cell death (ICD) (257, 258) and thus lead to
tumor regression even at distance sites, the so-called abscopal
effect (259, 260). Additionally, radiotherapy has been reported to
stimulate the expression of several molecules in cancer cells
including MHC class I, death receptors, adhesion molecules, Fas,
thus promoting CTL-mediated killing (261, 262). Therefore,
combinatorial strategies of irradiation with the therapeutic
cancer vaccine also constitute an attractive treatment option
(263–265) (Figures 2B and 3). However, radiotherapy is also
responsible of reducing tumor infiltrating effector cells during
the radiation regimen (266). Yet, the ultimate effect of
radiotherapy synergizing with cancer vaccines is partly due to
the vessel normalization that allows a better infiltration of T cells
enhanced by the vaccine (267). Another preclinical study
reported the best efficacy of vaccine when is administered 5
weeks after radiotherapy (268). In light of these findings, the
combinatorial strategy of radiotherapy and cancer vaccine has
more potential to succeed when radiotherapy is given first,
followed by the vaccine (269).UNDERSTANDING AND MANIPULATING
THE PATIENTS’ “LIFE-STYLE” TO
INCREASE VACCINE POTENCY
Although life expectancy has increased in Europe over the last 30
years, the so called “healthy life expectancy” has not, and many
suffer from some form of chronic disease in the last 9–11 years of
their life after the age of 65. In fact, 85% of deaths are caused by
chronic diseases such as cancer, cardiovascular disease, chronic
respiratory disease, diabetes, and mental illness, with 70 to 80%
of healthcare costs being dedicated to the treatment and
management of these conditions and diseases. Moreover,
whereas cardiovascular diseases are the main cause of death
after the age of 65, cancer remains the first and second cause of
death before and after the age of 65 respectively. Risk factors
known to be involved in chronic disease include repeat
infections, obesity, diet, tobacco, radiation and environmental
factors, all of which induce chronic disease through the induction
of inflammation. Correctly regulated acute inflammation is the
normal response to pathogens, irritants or damaged tissue,
whereas chronic inflammation results from a failure to
completely eliminate the pathogens, the inability to
enzymatically remove the irritant, the body turning against
self-proteins. However, chronic inflammation can also be the
results of recurrent acute inflammation. In recent years, the
importance of the microbiota has been revealed, including
alterations during chronic inflammation. Furthermore, more
recent work has highlighted how a disturbed microbiota
cannot only play a part in exacerbating inflammation but can
drive the process. For example, in immunotherapy against
cancer, studying a patient’s intestinal microbiota composition
can be used to stratify patients into “responders” versus “non-
responder” according to their intestinal microbiota composition
(270, 271). Indeed, in the study from V. Gopalakrishnan et al.,
2018 (271), patients with metastatic melanoma who respondedFebruary 2021 | Volume 11 | Article 615240
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were found to have a higher diversity of bacteria as well as a
significantly higher number of the Ruminococcaceae family in
their fecal microbiota. Interestingly, the prevalence of this family
of bacteria increases during alcohol abstinence and inversely
correlates with intestinal permeability (272). This species has also
been shown to have in vitro and in vivo anti-inflammatory
properties (273). Importantly, similar studies in mice have
demonstrated that response to treatment could be transferred
from responders to non-responders via fecal transplantation into
tumor-bearing germ-free mice (271). However, other studies
have shown the importance of other bacteria such as
Bifidobacterium longum , Collinsel la aerofaciens , and
Enterococcus faecium, and Akkermansia muciniphila the latter
being systematically found in higher number in patients with
advanced melanoma who respond to anti-PD-L1 treatment
(274), whereas patients with advanced urothelial carcinoma,
non-small cell lung cancer, and renal cell carcinoma who
received antibiotics before, during and after treatment all
experienced reduced progression-free survival and lower
overall survival rates, thereby demonstrating the importance of
not disturbing the microbiota (275).
Most cancer vaccines, including cancer vaccines, will require
some form of adjuvant to either induce/boost a response,
increase the speed of the response, allow for a more reduce
dose to be used and/or reduce the number of immunizations. In
view of the importance/influence the microbiota on a person’s
overall wellbeing and the immune system in particular, it is of
prime importance to understand ways to improve this
biodiversity, as well as to increase the number of “beneficial”
bacteria present in the patient’s intestinal microbiota before,
during and after vaccination. Increasing the diversity of bacteria
within the intestinal flora has been shown to improve metabolic
and immunological functions (276). No clear data is available
about cancer vaccine, but the efficacy of vaccination against
several pathogen has been clearly correlated with microbiota.
Microbiota can indeed act as a natural vaccine adjuvant and
specifically as ligand for different TLRs. Flagellin (TLR5 ligand)
from microbiota seems to play a crucial role since levels of TLR5
have been correlated to the magnitude of humoral response
(277). Recently, microbiota has also been reported to enhance
anti-tumor response when used as a real cancer vaccine adjuvant
in a murine model [EGFR vIII-expressing Listeria
vaccine, (278)].
In light of these results, the use of probiotics, or novel
genetically modified bacteria, may improve the efficacy of
cancer vaccine. In addition, the microbiota is sensitive and will
respond to physiological changes taking place in the host due to
internal and external factors such as lifestyle, exercise, diet and
the physiology of the host and this, in turn, will influence the
well-being of the host. Exercise has already been shown to have a
role in reducing the risk of cancer, and to be associated with a
lower incidence of cancer and a lower risk of recurrence (279,
280). These effects and associations have been linked with the
ability of exercise to influence immune cells such as NK, T cells,
B cells and DCs, all of which have been found at a higher densityFrontiers in Immunology | www.frontiersin.org 15within the tumors of animals who had been allowed to freely use
an exercise wheel (281). Out of all these cells, NK cells (which
express the highest number of b-adrenergic receptors) were the
most sensitive to exercise, in that they were recruited within
minutes after the start of exercise (282). These effects were shown
to be driven, at least in part, by exercise-induced increases in
catecholamine production (282). Moreover, the relationships
between the hypothalamic-pituitary-adrenal (HPA) axis, the
autonomic nervous system and the immune system and its
effect on the microbiota have previously been neglected and
certainly never been taken into account prior to, or during cancer
vaccine treatment. Yet, this Gut-Brain axis is bi-directional
whereby gut-microflora and brain communicate and are
influenced by each other’s signals via neural, endocrine,
humoral and immune links. Therefore, as highlighted above,
activities such as exercise which increases the level of
neurotransmitters such as catecholamines, and the
consumption of certain food such dietary fibers which will
increase the production of short chain fatty acids such as
butyrate, generated by anaerobic bacteria during fermentation
which in turn will influence the production of neuropeptide such
as NPY, will have a significant impact on the activation or
suppression of certain immune cells. Butyrate itself is a histone
deacetylase inhibitor that has been shown to suppress tumor
growth (283–285). NPY receptors are widely expressed on
immune cells, especially Y1R, which exists on almost every
type of immune cells, and have an important yet diverse role
on the immune system, having both negative as well as activator
functions (286) [For a full review on the immunomodulatory
activity of NPY please read Chen et al. (287)]. Targeting
selectively certain neuropeptide receptors will therefore open
more drug development to improve vaccine potency as well as
offer novel vaccine deliver system.
NPY levels often increase during stress responses, and NPY
receptors are shown to be overexpressed by many well-
innervated cancers such as prostate cancer, the trans-
differentiation of which into aggressive neuroendocrine
prostate cancer (NEPC) after a long period of androgen-
deprivation-therapy (ADT) treatments often leads to metastasis
progression and incurable disease. NEPC expresses high levels of
b2-adrenergic receptors (ADRs) which can be activated by
adrenergic signals triggered by depression or chronic stress,
which is prevalent in men with prostate cancer. Improving the
efficacy of immunotherapies will therefore require approaches to
attenuate the immunosuppressive nature of the tumor
microenvironment (TME), increase the biodiversity and the
number of “good” bacteria as well take into account the impact
of depression and chronic stress.
Although the precise mechanisms underlying such intricate
connections are only now starting to be elucidated there is
absolutely no doubt that they will need to be carefully assessed
if one wants to achieve optimum vaccine efficacy. However, most
of the scientific vaccine community is now focused on the
microbiota, forgetting the rest of the axis.
Therefore, future successful cancer therapy as well as
vaccination strategies may be those that approach the therapyFebruary 2021 | Volume 11 | Article 615240
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strategies that influence the life-style impacting the immune system.CONCLUSIONS
Therapeutic vaccines represent an attractive strategy to stimulate
the immune system against cancer in combination with standard
therapies. However, multiple cancer vaccines have not yet
achieved significant clinical efficacy. Their limited efficacy is
certainly in part related to the poor immunogenicity of the
vaccine itself in many cases, but also to the difficulty of
inducing an effective immune response in the compromised
immune system of cancer patients. Indeed, cancer cells
successfully grow by establishing an immunosuppressive tumor
microenvironment to protect themselves from host’s immune
attack. To add to this the median age of cancer patients is 66
years old and the immune system is known to become less
efficient and more dysregulated as people age. However, while on
the one hand the immune system declines over time, a
phenomenon known as immunosenescence, aging is also
known to be associated with a low, but persistent level of
inflammation, inflamm-aging , which a lso leads to
dysregulation of innate and adaptive immune cells. Therefore,
the choice of adjuvants in vaccine formulations needs careful
optimization for each vaccine as well as for each patient if the
maximum immune response and clinical efficacy in such a
compromised condition is to be achieved. Globally, given the
crucial role of CD8+ T cells in tumor control, adjuvants capable
of eliciting cellular response, rather than humoral, are certainly
preferable. Indeed, levels of CD8+ T cells induced after cancer
vaccine have been correlated with tumor regression in both
murine and clinical studies (256, 288). More specifically,
promising adjuvants are those that proved to favor dendritic
cells maturation (the principal APC in tumor context) and cross-
presentation. Among the formers, STINGs and TLR agonists
(especially CpG, albeit more in mice than in human and poly I:C)
demonstrated the most encouraging results. The induction of DC
maturation is in fact a crucial point in vaccine strategy to avoid
self-antigens tolerance. In addition, given the defects on DCs
described in elderly individuals, TLR ligands likely represent the
most promising immunomostimulatory adjuvant candidates for
cancer vaccines in these patients. Beside the maturation of DCs,
the ideal vaccine formulation should also favor the cross-
presentation of antigens to CD8+ T cells by DCs. In that
respect, several vectors are under development. Although live
vectors from virus or bacteria can efficiently induce cross-
presentation of antigens, the vector itself being immunogenic,
elicits an immune response. Therefore, after the first dose of
vaccine, the subsequent boost doses need to use different vectors
in order to overcome the neutralization of vectorized vaccine by
host immunity. Consequently, this approach has limited
prospects in clinical practice. Other not live vectors showed
interesting results in mice, such as liposomes, virosomes or
nanoparticles. They have the advantage of being able to deliver
different source of antigens (RNA, DNA, proteins, peptides, …)Frontiers in Immunology | www.frontiersin.org 16and adjuvants and also be immunostimulatory by assembling
both molecules in a package and carry it to secondary lymphoid
organs. Compared to classic depot adjuvants such as IFA or
MF59, these vectors, allow antigens to reach directly the lymph
nodes in order to induce a more efficient cross-presentation
between DCs and T cells. The use of these adjuvants may thus
overcome the detrimental effect that some study reported for W/
O emulsions, related to the persistent release of antigen and the
inflammation in the injection site. In fact, if in one hand the slow
release of antigen may promote a stronger immune response, on
the other hand it can lead to T cell anergy if DCs are immatures
or T cell sequestration at the injection site has occurred.
However, although very promising, vector adjuvants have not
yet demonstrated convincing efficacy in humans.
In the light of these results, not-depot adjuvants are thus
preferable, but the schedule of this particular type of vaccination
is still a crucial point, and unfortunately not directly addressed in
clinical trials and only rarely in pre-clinal studies. A too short
period between boost and priming vaccinations might indeed
lead to immunological tolerance against the antigens. In a mouse
model, Wick et al. reported a decline of response from 30% to
15% (circulating specific T cells) by day 10 of daily vaccinations
with a formulation using poly I:C and OVA protein (289).
Another study by Stark et al. showed similar results in a B16-
OVA melanoma model using a vaccine formulation with archae
liposoms (archaeosomes) (290). In this study, the authors
vaccinated mice with a regular interval of 0, 21, 42, 72 and 110
days and a decline of response was seen after the third dose.
However, beside the potency of immunological response
(amount of specific T cells) induced at the time of vaccination,
it is also important to achieve a prolonged tumor protection. This
latter has been particularly correlated with a central memory
phenotype (CD62Lhigh) of vaccine-induced T cells, rather than
effector memory (CD62Llow). In that respect, interestingly, in the
prophylactic model of Stark et al. even if a single dose of vaccine
triggered a lower frequency of antigen-specific CD8 T cells than
multiple doses, the late tumor protection was similar (tumor
challenge on day 323). These results highlight the importance of
the quality of the immunological response besides the quantity.
Lastly, different combinatorial approaches are being explored
trying to enhance the efficacy of the vaccine. Despite the
numerous encouraging results in pre-clinical studies, clinical
responses to cancer vaccine as monotherapy have been rather
anecdotal so far and they are mostly reported in case of pre-
neoplastic lesions or low tumor burden. However, the goal of a
therapeutic cancer vaccine should be to improve survival in
patients with advanced cancers. In this common situation, the
immune response elicited by the vaccine needs to be particularly
strong to face the suppressive nature of the tumormicroenvironment
and more generally the immunocompromised system of the patients
in this context, associating different adjuvants, especially an
immunostimulatory molecule with a vector adjuvant, may
certainly improve the efficacy of the vaccine. In addition,
combining cancer vaccine with other treatments is more likely to
succeed, but early intervention may also be of value. Several
combinatorial strategies are being explored, such as with anti-February 2021 | Volume 11 | Article 615240
Cuzzubbo et al. Cancer Vaccines: Adjuvant Potencyangiogenic treatments to promote T cell homing to tumors, with
immune checkpoint inhibitors to enhance CTL function, and also
with standard anti-cancer therapies such as chemotherapy to deplete
immunosuppressive leucocyte populations, and radiotherapy to
favor antigen-presentation by cancer cells. As mentioned, a crucial
point, rarely addressed in clinical trials, is the optimal timing
of such therapies. In the light of the synergic mechanism
specifically involved, therapies acting through the clearance of
immunosuppressive cells such as radiotherapy and chemotherapy
should be given prior to vaccination, whereas immunostimulatory
agents enhancing the anti-tumor response of the vaccine should be
administered concomitantly with the vaccine (preferentially at the
boost dose) as in the case of immune checkpoint inhibitors. It may
also be favorable to use vaccines in combination with early surgical
intervention as the size of the lesionmay hamper effective infiltration
into the tumor. If the early intervention is used, then therapy effects
could be achieved without a risk for immune suppression. Also, the
host is less likely to have been negatively impacted by the tumor,
immobilization and/or toxic drugs, making the patient more likely to
still have a healthy and functional immune system.
In addition to these more traditional approaches, more
clinical trials should consider implementing changes in the
diet/exercise/stress level of the patients, while the patients areFrontiers in Immunology | www.frontiersin.org 17recovering from other more aggressive form of treatments
(chemotherapy, radiotherapy) in order to re-establish a
functional more effective immune system prior to the
administration of a vaccine and carefully monitor the effect
these will have on the diversity/quantity of their microbiome
and their immune status, before and after vaccination in order to
assess their impact and overall benefit for the patients.AUTHOR CONTRIBUTIONS
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